Home » Stocks » ADAP

Adaptimmune Therapeutics PLC (ADAP)

Stock Price: $5.75 USD 0.15 (2.59%)
Updated Jan 25, 2021 2:36 PM EST - Market open
Market Cap 866.76M
Revenue (ttm) 3.18M
Net Income (ttm) -122.84M
Shares Out 928.02M
EPS (ttm) -0.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $5.75
Previous Close $5.60
Change ($) 0.15
Change (%) 2.59%
Day's Open 5.68
Day's Range 5.57 - 5.96
Day's Volume 646,216
52-Week Range 2.25 - 12.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 month ago

Immense potential, TCR therapy leader, but early stage. Science looks excellent with some proof of concept but risks, especially toxicity risks, abound.

GlobeNewsWire - 2 months ago

- SPEARHEAD-1 enrolment on track; planning to launch ADP-A2M4 in 2022 in the US for people with synovial sarcoma -

GlobeNewsWire - 2 months ago

- Data support confidence in SPEARHEAD-1 as a registrational trial -

GlobeNewsWire - 2 months ago

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will host a virtual Invest...

GlobeNewsWire - 2 months ago

- Data support continued development of ADP-A2M4CD8 -

The Motley Fool - 2 months ago

Adaptimmune Therapeutics and Trillium Therapeutics could be big winners for early shareholders.

Other stocks mentioned: TRIL
Seeking Alpha - 2 months ago

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients -

GlobeNewsWire - 3 months ago

PHILADELPHIA and OXFORDSHIRE, U.K., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and pr...

The Motley Fool - 3 months ago

An early abstract release has shareholders in panic mode today.

GlobeNewsWire - 3 months ago

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware o...

InvestorPlace - 4 months ago

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

Other stocks mentioned: CCXI, KOD, MCRB, MYOV, NVAX, SRNE
Seeking Alpha - 4 months ago

Following the resurgence from the coronavirus bear market of 2020, Adaptimmune yielded multiple fold gains from its lows earlier in the year.

GlobeNewsWire - 4 months ago

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, presente...

Zacks Investment Research - 5 months ago

Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Seeking Alpha - 5 months ago

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 -

GlobeNewsWire - 6 months ago

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 23, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the Europ...

GlobeNewsWire - 6 months ago

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial re...

Zacks Investment Research - 7 months ago

As of late, it has definitely been a great time to be an investor in Adaptimmune Therapeutics plc (ADAP).

Zacks Investment Research - 7 months ago

Adaptimmune Therapeutics (ADAP) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

The Motley Fool - 7 months ago

Can an early-stage cancer immunotherapy company deliver riches to shareholders?

The Motley Fool - 7 months ago

The biotech continued its winning ways.

GlobeNewsWire - 7 months ago

PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 04, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today an...

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Adaptimmune Therapeutics (ADAP) stock based on the movements in the options market lately.

GlobeNewsWire - 7 months ago

PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today an...

The Motley Fool - 7 months ago

Adaptimmune prudently decided to take advantage of its soaring share price to raise capital.

Market Watch - 7 months ago

Shares of Adaptimmune Therapeutics PLC ADAP, +127.77% tumbled 11% in premarket trading Monday, after the biopharmaceutical company focused on cancer treatments said it planned a public offerin...

GlobeNewsWire - 7 months ago

PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today an...

The Motley Fool - 7 months ago

Positive results from a handful of patients treated have bolstered confidence in the company's cell-based approach to cancer treatment.

Benzinga - 7 months ago

Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) shares were advancing strongly Friday following an updated clinical readout from the company.

24/7 Wall Street - 7 months ago

Adaptimmune Therapeutics PLC (NASDAQ: ADAP) shares jumped on Friday after the company announced updated data from its early-stage clinical trial in patients with lung, head and neck cancers.

GlobeNewsWire - 7 months ago

- New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy -

The Motley Fool - 8 months ago

Big pharma partners could help this cutting-edge cell-therapy company be successful in the future.

Seeking Alpha - 8 months ago

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2020 Results - Earnings Call Transcript

Benzinga - 8 months ago

Shares of Adaptimmune Therapeutics (NASDAQ:ADAP) rose 1.3% in pre-market trading after the company reported Q1 results.

GlobeNewsWire - 8 months ago

- Upfront payment of $50m received from Astellas and approximately $90m offering completed -

Zacks Investment Research - 8 months ago

Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

GlobeNewsWire - 8 months ago

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the Euro...

The Motley Fool - 9 months ago

Adaptimmune Therapeutics and OrganiGram Holdings are two penny stocks that may be worth the risk.

Other stocks mentioned: OGI
The Motley Fool - 9 months ago

These three clinical-stage biotechs are all bargains after last month's marketwide downturn.

Other stocks mentioned: BCEL, CRSP
The Motley Fool - 10 months ago

These clinical-stage drugmakers could be a steal at current levels.

Other stocks mentioned: AGEN, GILD, VKTX
Seeking Alpha - 10 months ago

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q4 2019 Results - Earnings Call Transcript

The Motley Fool - 11 months ago

Can these soaring biotech stocks keep climbing?

Other stocks mentioned: AVXL, BTAI
The Motley Fool - 11 months ago

These top growth stocks could dramatically improve your financial wellbeing.

Other stocks mentioned: AMRN, APHA, BCYC, NVAX, PBYI
The Motley Fool - 11 months ago

These three clinical-stage biotechs could all double in value before year's end.

Other stocks mentioned: APLT, KNSA
GlobeNewsWire - 11 months ago

PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today...

Zacks Investment Research - 11 months ago

Is (ADAP) Outperforming Other Medical Stocks This Year?

Seeking Alpha - 11 months ago

Adaptimmune's Data In Treating Solid Tumors Reinforces Prior Data And Highlights Technology Platform

GlobeNewsWire - 1 year ago

PHILADELPHIA, Pa. and OXFORD, United Kingdom, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today ...

About ADAP

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarc... [Read more...]

Industry
Biotechnology
IPO Date
May 6, 2015
CEO
Adrian G. Rawcliffe
Employees
420
Stock Exchange
NASDAQ
Ticker Symbol
ADAP
Full Company Profile

Financial Performance

In 2019, ADAP's revenue was $1.12 million, a decrease of -98.11% compared to the previous year's $59.51 million. Losses were -$137.17 million, 43.6% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for ADAP stock is "Buy." The 12-month stock price forecast is 11.33, which is an increase of 97.21% from the latest price.

Price Target
$11.33
(97.21% upside)
Analyst Consensus: Buy